Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The NeoGlioma Study
NCT05030298Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- May 2023
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in high-grade glioma (HGG), sponsored by Mayo Clinic. Primary endpoints: Proportion of patients experiencing any acute grade 3 or greater unplanned adverse event, Acute clinical toxicity profile and 1 more. Started May 2023; status: recruiting.
02
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT05030298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030298.